B+
Bull case
20%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
DSGN
Design TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+53.1
Score
AI commentary
The primary Q2 release is constructive on program progress and cash runway, but forward visibility is concentrated in Q4 2026 registrational planning and Q1 2027 RESTORE-FA data. The earnings queue labels August 10, while the available company release and SEC exhibit are dated August 3; the primary filing date is used here. No reliable post-print analyst revision or target-change set was available, so the view remains monitoring-oriented despite the reported $21 median target.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-03eventQ2 2026 operating update and RESTORE-FA redesignHigh impact
The company reported $207.4 million of cash and securities, initiated DT-818 dosing in DM1, and modified RESTORE-FA around a planned 1 mpk dose, a 12-week cohort, and an FXN protein endpoint [#SEC-8K-2026-08-03].
2026-11-11eventRESTORE-FA registrational-plan updateHigh impact
Management expects to provide an update on registrational plans for DT-216P2 in the fourth quarter of 2026 [#SEC-8K-2026-08-03].
2027-08-13catalystRESTORE-FA 12-week dataHigh impact
Data from the 12-week treatment cohort is expected in the first quarter of 2027. Positive biomarker and clinical findings could materially de-risk DT-216P2, but the outcome remains binary [#SEC-8K-2026-08-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology